Lilly Cuts Price of Zepbound Vials to Battle Cheaper Copycats

Lilly Cuts Zepbound Price to Combat Cheaper Copycats
Lock
This article is for subscribers only.

Eli Lilly & Co. is ramping up the fight against cheaper, copycat versions of Zepbound by lowering prices for a version of its blockbuster obesity drug.

The company is reducing the cost of its 2.5 milligram and 5 milligram Zepbound vials to $349 and $499 a month, respectively, according to a statementBloomberg Terminal. That’s about $50 less than current prices.